Wen-Lung Ma, Ph.D.
Affiliations: | 2010 | University of Rochester, Rochester, NY |
Area:
PathologyGoogle:
"Wen-Lung Ma"Mean distance: 10177.7
Parents
Sign in to add mentor| Chawnshang Chang | grad student | 2010 | Rochester | |
| (Androgen receptor roles in the liver: Homeostasis and cancer.) | ||||
BETA: Related publications
See more...
Publications
|
You can help our author matching system! If you notice any publications incorrectly attributed to this author, please sign in and mark matches as correct or incorrect. |
| Chung WM, Chen L, Chang WC, et al. (2021) Androgen/Androgen Receptor Signaling in Ovarian Cancer: Molecular Regulation and Therapeutic Potentials. International Journal of Molecular Sciences. 22 |
| Lai HC, Chung WM, Chang CM, et al. (2020) Androgen Receptor Enhances the Efficacy of Sorafenib Against Hepatocellular Carcinoma Through Enriched EpCAM Stemness. Anticancer Research. 40: 1285-1295 |
| Yang JC, Chang N, Wu DC, et al. (2019) Preclinical evaluation of exemestane as a novel chemotherapy for gastric cancer. Journal of Cellular and Molecular Medicine |
| Chung WM, Ho YP, Chang WC, et al. (2019) Increase Paclitaxel Sensitivity to Better Suppress Serous Epithelial Ovarian Cancer via Ablating Androgen Receptor/Aryl Hydrocarbon Receptor-ABCG2 Axis. Cancers. 11 |
| Lin VC, Huang SP, Ting HJ, et al. (2017) Vitamin D receptor-binding site variants affect prostate cancer progression. Oncotarget. 8: 74119-74128 |
| Hsu CL, Liu JS, Lin TW, et al. (2017) Characterization of a novel androgen receptor (AR) coregulator RIPK1 and related chemicals that suppress AR-mediated prostate cancer growth via peptide and chemical screening. Oncotarget. 8: 69508-69519 |
| Lin VC, Huang SP, Ting HJ, et al. (2017) Vitamin D receptor-binding site variants affect prostate cancer progression. Oncotarget |
| Hsu CL, Liu JS, Lin TW, et al. (2017) Characterization of a novel androgen receptor (AR) coregulator RIPK1 and related chemicals that suppress AR-mediated prostate cancer growth via peptide and chemical screening. Oncotarget |
| Xu J, Lin H, Li G, et al. (2016) Sorafenib with ASC-J9® synergistically suppresses the HCC progression via altering the pSTAT3-CCL2/Bcl2 signals. International Journal of Cancer |
| Lai HC, Yeh CC, Jeng LB, et al. (2016) Androgen receptor mitigates postoperative disease progression of hepatocellular carcinoma by suppressing CD90+ populations and cell migration and by promoting anoikis in circulating tumor cells. Oncotarget |